Specific immunoglobulin isotypes correlate with disease activity, morphology, duration and HLA association in Pemphigus vulgaris

Autoimmunity

Volumn 45, Issue 7, 2012, Pages 516-526

  Dhandha, Maulik M ^a   Seiffert Sinha, Kristina ^b   Sinha, Animesh A ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Autoantibodies; Desmoglein 3; ELISA; Humoral; Immunoprofiling

Indexed keywords

HLA ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; ONSET AGE; PEMPHIGUS VULGARIS; PHENOTYPE; REMISSION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODY SPECIFICITY; AUTOANTIBODIES; CASE-CONTROL STUDIES; DESMOGLEIN 3; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN ISOTYPES; MALE; MIDDLE AGED; PEMPHIGUS; SEX FACTORS; YOUNG ADULT;

EID: 84867095467     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.702811     Document Type: Article

References (55)

1. Hertl M. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 2000; 122(2):91-100.
2. Schmidt E, Brocker EB, Zillikens D. Pemphigus. Verlust des desmosomalen Zell-Zell-Kontaktes [Pemphigus. Loss of desmosomal cell-cell contact]. Hautarzt 2000;51(5):309-318.
3. Spaeth S, Riechers R, Borradori L, et al. IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris. Br J Dermatol 2001;144(6):1183-1188.
4. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991;67(5):869-877.
5. Lee E, Lendas KA, Chow S, et al. Disease relevant HLA class II alleles isolated by genotypic, haplotypic, and sequence analysis in North American Caucasians with pemphigus vulgaris. Hum Immunol 2006;67(1-2):125-139.
6. Sinha AA, Brautbar C, Szafer F, et al. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 1988;239(4843):1026-1029.
7. Sinha AA, Lopez MT, McDevitt HO. Autoimmune diseases: the failure of self tolerance. Science 1990;248(4961): 1380-1388.
8. Todd JA, Acha-Orbea H, Bell JI, et al. A molecular basis for MHC class II-associated autoimmunity. Science 1988; 240(4855):1003-1009.
9. Hertl M, Amagai M, Sundaram H, et al. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol 1998;110(1):62-66.
10. Lin MS, Swartz SJ, Lopez A, et al. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 1997;99(1):31-40.
11. Rizzo C, Fotino M, Zhang Y, et al. Direct characterization of human T cells in pemphigus vulgaris reveals elevated autoantigen-specific Th2 activity in association with active disease. Clin Exp Dermatol 2005;30(5):535-540.
12. Wucherpfennig KW, Yu B, Bhol K, et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 1995;92(25): 11935-11939.
13. Chow S, Rizzo C, Ravitskiy L, et al. The role of T cells in cutaneous autoimmune disease. Autoimmunity 2005;38(4): 303-317.
14. Hertl M, Veldman C. Pemphigus-paradigm of autoantibodymediated autoimmunity. Skin Pharmacol Appl Skin Physiol 2001;14(6):408-418.
15. Cirillo N, Gombos F, Lanza A. Pemphigus vulgaris immunoglobulin G can recognize a 130 000 MW antigen other than desmoglein 3 on peripheral blood mononuclear cell surface. Immunology 2007;121(3):377-382.
16. Evangelista F, Dasher DA, Diaz LA, et al. E-cadherin is an additional immunological target for pemphigus autoantibodies. J Invest Dermatol 2008;128(7):1710-1718.
17. Kalantari-Dehaghi M, Molina DM, Farhadieh M, et al. New targets of pemphigus vulgaris antibodies identified by protein array technology. Exp Dermatol 2011;20(2):154-156.
18. Kurzen H, Brenner S. Significance of autoimmunity to nondesmoglein targets in pemphigus. Autoimmunity 2006;39(7): 549-556.
19. Nguyen VT, Ndoye A, Shultz LD, et al. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000; 106(12):1467-1479.
20. Kalish RS. Pemphigus vulgaris: the other half of the story. J Clin Invest 2000;106(12):1433-1435.
21. Ayatollahi M, Joubeh S, Mortazavi H, et al. IgG4 as the predominant autoantibody in sera from patients with active state of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2004;18(2):241-242.
22. Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994;189(Suppl 1):85-89.
23. David M, Katzenelson V, Hazaz B, et al. Determination of IgG subclasses in patients with pemphigus with active disease and in remission. Arch Dermatol 1989;125(6):787-790.
24. Hacker MK, Janson M, Fairley JA, et al. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin Immunol 2002;105(1):64-74.
25. Jones CC, Hamilton RG, Jordon RE. Subclass distribution of human IgG autoantibodies in pemphigus. J Clin Immunol 1988;8(1):43-49.
26. Kim YH, Geoghegan WD, Jordon RE. Pemphigus immunoglobulin G subclass autoantibodies: studies of reactivity with cultured human keratinocytes. J Lab Clin Med 1990;115(3): 324-331.
27. Yamada H, Hashimoto T, Nishikawa T. IgG subclasses of intercellular and basement membrane zone antibodies: the relationship to the capability of complement fixation. J Invest Dermatol 1989;92(4):585-587.
28. Kricheli D, David M, Frusic-Zlotkin M, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their firstdegree relatives. Br J Dermatol 2000;143(2):337-342.
29. Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010;134(3):320-330.
30. Futei Y, Amagai M, Ishii K, et al. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci 2001;26(1):55-61.
31. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58(6):1043-1046.
32. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39(5):225-235.
33. Hamilton RG, Morrison SL. Epitope mapping of human immunoglobulin- specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies. J Immunol Meth 1993;158(1):107-122.
34. Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999;140(2):351-357.
35. Bhol K, Natarajan K, Nagarwalla N, et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 1995;92(11): 5239-5243.
36. Amagai M, Tsunoda K, Zillikens D, et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999;40(2 Pt 1): 167-170.
37. Yoshida K, Takae Y, Saito H, et al. Cutaneous type pemphigus vulgaris: a rare clinical phenotype of pemphigus. J Am Acad Dermatol 2005;52(5):839-845.
38. Mimouni D, Bar H, Gdalevich M, et al. Pemphigus-analysis of epidemiological factors in 155 patients. J Eur Acad Dermatol Venereol 2008;22(10):1232-1235.
39. Robinson WH, Steinman L, Utz PJ. Protein arrays for autoantibody profiling and fine-specificity mapping. Proteomics 2003;3(11):2077-2084.
40. Hueber W, Utz PJ, Steinman L, et al. Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 2002;4(5):290-295.
41. Sinha AA. Constructing immunoprofiles to deconstruct disease complexity in pemphigus. Autoimmunity 2012;45(1):36-43.
42. Warren SJ, Arteaga LA, Rivitti EA, et al. The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus. J Invest Dermatol 2003;120(1):104-108.
43. Suzuki M, Harada S, Kanazawa K, et al. Relationship between antigens and IgG subclasses in bullous pemphigoid. Autoimmunity 1994;18(3):217-225.
44. Brooks WS, Lee YY, Abell E, et al. Comparison of IgG subclasses and complement binding activity of autoantibodies from patients with bullous pemphigoid and pemphigus. J Clin Lab Anal 1989;3(5):307-311.
45. Brandsen R, Frusic-Zlotkin M, Lyubimov H, et al. Circulating pemphigus IgG in families of patients with pemphigus: comparison of indirect immunofluorescence, direct immunofluorescence, and immunoblotting. J AmAcad Dermatol 1997; 36(1):44-52.
46. Dmochowski M, Hashimoto T, Nishikawa T. The analysis of IgG subclasses of anti-intercellular antibodies in pemphigus by an immunoblot technique. Arch Dermatol Res 1992;284(5): 309-311.
47. Shirakata Y, Shiraishi S, Sayama K, et al. Subclass characteristics of IgG autoantibodies in bullous pemphigoid and pemphigus. J Dermatol 1990;17(11):661-666.
48. Belloni-Fortina A, Faggion D, Pigozzi B, et al. Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol 2009:187864.
49. Manz RA, Hauser AE, Hiepe F, et al. Maintenance of serum antibody levels. Annu Rev Immunol 2005;23: 367-386.
50. Harman KE, Gratian MJ, Bhogal BS, et al. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol 2000;143(2):343-348.
51. Mahoney MG, Wang Z, Rothenberger K, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999;103(4): 461-468.
52. Amagai M, Ahmed AR, Kitajima Y, et al. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"? Exp Dermatol 2006;15(10):815-831.
53. Saha M, Harman K, Mortimer NJ, et al. Pemphigus vulgaris in White Europeans is linked with HLA Class II allele HLA DRB1*1454 but not DRB1*1401. J Invest Dermatol 2010; 130(1):311-314.
54. Aalberse RC, Stapel SO, Schuurman J, et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009;39(4): 469-477.
55. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000;42(3):422-427.